Synmosa's Posts Highest Single-Quarter Earnings Ever, EPS Hits NT$1.35

Date:2016.05.09

Synmosa Biopharma (TPEx:4114) recently announced its first quarter revenue reached NT$485 million (about US$16 million), underscoring the company's continued success in the wake of a blockbuster year in 2015 with an all-time record high earnings for a single quarter. Year-over-year revenue for the current quarter has shown a marked increase in growth by nearly 20%. Synmosa has continued its multifaceted approach of allocating resources in the most efficient way including ramping up production of the Group's portfolio of drugs for treating respiratory, urinary tract, and cardiovascular illnesses, resulting in a substantial increase in revenue. In addition, Synmosa has successfully expanded into the self-pay market for pharmaceutical products, incorporated niche market products and development of newly patented drugs, as well as executed a series of acquisitions within the industry. Meanwhile, Synmosa has been bolstered by holding a controlling stake in Health Chemical Pharmaceutical — which has seen sustained sales growth in its main product lines including Jensheng Enema and Compound Glycyrrhiza Oral Solution. As a result, projections for 2016 show that Synmosa will continue to achieve increasing growth and record high revenue.